<?xml version="1.0" encoding="UTF-8"?>
<drug type="biotech" created="2015-11-30" updated="2019-12-02">
  <drugbank-id primary="true">DB09446</drugbank-id>
  <name>Safflower oil</name>
  <description>Safflower (_Carthamus tinctorius_ L) is a herbaceous plant in the Asteraceae family. Extracted from the seeds of safflowers, safflower oil is a rich source of various saturated fatty acids, monounsaturated fatty acid (oleic acid) or essential n-6 polyunsaturated fatty acid (PUFA) linoleic acid [A32677, A32679], depending on the flower type. Safflower oil with a higher content of polyunsaturated fatty acids is more commonly used as an edible oil. The constituents of safflower oil also include alpha-tocopherol, gamma-tocopherol, and mixed [DB11251] [A32692].  Safflower oil is approved for use as an indirect additive in food contact substances and is readily available as a food ingredient. Gamma linolenic acid (GLA) safflower oil is marketed as an over-the-counter dietary supplement.</description>
  <cas-number>8001-23-8</cas-number>
  <unii>65UEH262IS</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A32677</ref-id>
        <pubmed-id>21295383</pubmed-id>
        <citation>Asp ML, Collene AL, Norris LE, Cole RM, Stout MB, Tang SY, Hsu JC, Belury MA: Time-dependent effects of safflower oil to improve glycemia, inflammation and blood lipids in obese, post-menopausal women with type 2 diabetes: a randomized, double-masked, crossover study. Clin Nutr. 2011 Aug;30(4):443-9. doi: 10.1016/j.clnu.2011.01.001. Epub 2011 Feb 3.</citation>
      </article>
      <article>
        <ref-id>A32678</ref-id>
        <pubmed-id>10923778</pubmed-id>
        <citation>Sato M, Yoshida S, Nagao K, Imaizumi K: Superiority of dietary safflower oil over olive oil in lowering serum cholesterol and increasing hepatic mRnas for the LDL receptor and cholesterol 7alpha-hydroxylase in exogenously hypercholesterolemic (exHC) rats. Biosci Biotechnol Biochem. 2000 Jun;64(6):1111-7. doi: 10.1271/bbb.64.1111.</citation>
      </article>
      <article>
        <ref-id>A32679</ref-id>
        <pubmed-id>7595099</pubmed-id>
        <citation>Cox C, Mann J, Sutherland W, Chisholm A, Skeaff M: Effects of coconut oil, butter, and safflower oil on lipids and lipoproteins in persons with moderately elevated cholesterol levels. J Lipid Res. 1995 Aug;36(8):1787-95.</citation>
      </article>
      <article>
        <ref-id>A32692</ref-id>
        <pubmed-id>17466237</pubmed-id>
        <citation>Masterjohn C: The anti-inflammatory properties of safflower oil and coconut oil may be mediated by their respective concentrations of vitamin E. J Am Coll Cardiol. 2007 May 1;49(17):1825-6. doi: 10.1016/j.jacc.2007.04.001. Epub 2007 Apr 16.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L2465</ref-id>
        <title>SAFFLOWER OIL - National Library of Medicine HSDB Database - Toxnet - NIH</title>
        <url>https://toxnet.nlm.nih.gov/cgi-bin/sis/search/a?dbs+hsdb:@term+@DOCNO+5153</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>No approved therapeutic indications.</indication>
  <pharmacodynamics>Safflower oil contains n-6 polyunsaturated fatty acids (PUFAs) such as conjugated linoleic acid (CLA) which may have lipid-lowering and anti-inflammatory actions, as well as tocopherols. In a study of post-menopausal, obese women with type 2 diabetes, safflower oil supplementation was associated with improved metabolic endpoints including HbA1c, fasting glucose, insulin sensitivity estimated by QUICKI, HDL cholesterol, CRP, and adiponectin [A32677]. </pharmacodynamics>
  <mechanism-of-action>Linoleic acid in safflower oil may decrease serum cholesterol levels by activating hepatic uptake and biliary excretion of serum cholesterol [A32678]. Tocopherol in safflower oil is a radical scavenger with antioxidant properties. </mechanism-of-action>
  <toxicity>The LD50 in rats is &gt;5.0 g/kg following oral administration and &gt;50 g/kg following intraperitoneal administration [L2465].</toxicity>
  <metabolism>No pharmacokinetic data available. </metabolism>
  <absorption>Fatty acids and tocopherol from safflower oil are expected to undergo absorption within the digestive tract. </absorption>
  <half-life>No pharmacokinetic data available. </half-life>
  <protein-binding>No pharmacokinetic data available. </protein-binding>
  <route-of-elimination>No pharmacokinetic data available. </route-of-elimination>
  <volume-of-distribution>No pharmacokinetic data available. </volume-of-distribution>
  <clearance>No pharmacokinetic data available. </clearance>
  <salts/>
  <synonyms>
    <synonym language="english" coder="inn">Carthamus tinctorius seed oil</synonym>
  </synonyms>
  <products>
    <product>
      <name>Carthaphy Cap</name>
      <labeller>Phyto Health Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00290173</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1973-12-31</started-marketing-on>
      <ended-marketing-on>2003-11-27</ended-marketing-on>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Liposyn II</name>
      <labeller>Hospira, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0409-9786</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-08-27</started-marketing-on>
      <ended-marketing-on>2011-02-01</ended-marketing-on>
      <dosage-form>Injection, emulsion</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>NDA018997</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Liposyn II</name>
      <labeller>Hospira, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0409-9789</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-08-27</started-marketing-on>
      <ended-marketing-on>2011-02-01</ended-marketing-on>
      <dosage-form>Injection, emulsion</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>NDA018991</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Liposyn II 10%</name>
      <labeller>Hospira Healthcare Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00720976</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1987-12-31</started-marketing-on>
      <ended-marketing-on>2014-08-01</ended-marketing-on>
      <dosage-form>Emulsion</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Liposyn II 20%</name>
      <labeller>Hospira Healthcare Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00720968</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1987-12-31</started-marketing-on>
      <ended-marketing-on>2014-08-01</ended-marketing-on>
      <dosage-form>Emulsion</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Liposyn II Inj 10%</name>
      <labeller>Hospira Healthcare Ulc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00818712</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-01-01</started-marketing-on>
      <ended-marketing-on>2014-08-01</ended-marketing-on>
      <dosage-form>Emulsion</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Liposyn II</name>
      <ingredients>Egg phospholipids + Safflower oil + Soybean oil</ingredients>
    </mixture>
    <mixture>
      <name>Liposyn II</name>
      <ingredients>Egg phospholipids + Safflower oil + Soybean oil</ingredients>
    </mixture>
    <mixture>
      <name>Carthaphy Cap</name>
      <ingredients>Pyridoxine + Safflower oil</ingredients>
    </mixture>
    <mixture>
      <name>Liposyn II Inj 10%</name>
      <ingredients>Egg phospholipids + Safflower oil + Soybean oil</ingredients>
    </mixture>
    <mixture>
      <name>Liposyn II 20%</name>
      <ingredients>Egg phospholipids + Safflower oil + Soybean oil</ingredients>
    </mixture>
    <mixture>
      <name>Liposyn II 10%</name>
      <ingredients>Egg phospholipids + Safflower oil + Soybean oil</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Biological Products</category>
      <mesh-id>D001688</mesh-id>
    </category>
    <category>
      <category>Complex Mixtures</category>
      <mesh-id>D045424</mesh-id>
    </category>
    <category>
      <category>Diet, Food, and Nutrition</category>
      <mesh-id>D000066888</mesh-id>
    </category>
    <category>
      <category>Dietary Fats</category>
      <mesh-id>D004041</mesh-id>
    </category>
    <category>
      <category>Dietary Fats, Unsaturated</category>
      <mesh-id>D004042</mesh-id>
    </category>
    <category>
      <category>Fats</category>
      <mesh-id>D005223</mesh-id>
    </category>
    <category>
      <category>Fats, Unsaturated</category>
      <mesh-id>D005224</mesh-id>
    </category>
    <category>
      <category>Food</category>
      <mesh-id>D005502</mesh-id>
    </category>
    <category>
      <category>Food and Beverages</category>
      <mesh-id>D019602</mesh-id>
    </category>
    <category>
      <category>Lipids</category>
      <mesh-id>D008055</mesh-id>
    </category>
    <category>
      <category>Oils</category>
      <mesh-id>D009821</mesh-id>
    </category>
    <category>
      <category>Physiological Phenomena</category>
      <mesh-id>D010829</mesh-id>
    </category>
    <category>
      <category>Plant Oils</category>
      <mesh-id>D010938</mesh-id>
    </category>
    <category>
      <category>Plant Preparations</category>
      <mesh-id>D028321</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, emulsion</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Emulsion</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB09446.pdf?1524600504</msds>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <sequences/>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>Insoluble</value>
      <source>National Library of Medicine HSDB Database</source>
    </property>
    <property>
      <kind>Boiling Point</kind>
      <value>338-366</value>
      <source>National Library of Medicine HSDB Database</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>6652</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Safflower_oil</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>